India Acute Intermittent Porphyria Market (2026-2032) | Forecast, Size & Revenue, Value, Growth, Segmentation, Analysis, Companies, Competitive Landscape, Trends, Outlook, Industry, Share

India Acute Intermittent Porphyria Market Growth Rate

According to 6Wresearch internal database and industry insights, the India Acute Intermittent Porphyria Market is projected to grow at a substantial compound annual growth rate (CAGR) of 9.4% during the forecast period of 2026–2032.

India Acute Intermittent Porphyria Market Year-wise Growth Rate and Key Drivers (2022–2032)

This graph illustrates the annual growth rates of the India Acute Intermittent Porphyria Market from 2022 to 2032, highlighting market expansion supported by increasing awareness of rare diseases, improvements in diagnostic capabilities, growing access to specialized healthcare services, and rising adoption of advanced treatment options for rare metabolic disorders.

The table below provides a summary of the historical and forecasted growth rates of the India Acute Intermittent Porphyria Market, along with the rationale behind the performance of each year.

Topics Covered in the India Acute Intermittent Porphyria Market Report

The India Acute Intermittent Porphyria Market report covers the market by diagnosis, treatment, and end users. The report provides a detailed analysis of ongoing market trends, opportunities/high-growth areas, and market drivers that will help stakeholders align strategies based on current and future market dynamics.

India Acute Intermittent Porphyria Market Highlights

India Acute Intermittent Porphyria Market Synopsis

The India Acute Intermittent Porphyria Market is anticipated to witness steady growth during the forecast period on account of increase in awareness regarding rare genetic disorders, improvement in diagnostic capabilities, and growth in availability of advanced therapies. The rise in healthcare expenditure, specialized treatment centers, and government initiatives for rare diseases are contributing to the market growth.

Evaluation of Growth Drivers in India Acute Intermittent Porphyria Market (2026–2032)

Below are some major drivers and their influence on the market dynamics:

The India Acute Intermittent Porphyria Industry is projected to grow at a CAGR of 9.4% during 2026–2032 on account of increase in investments in rare disease research, improved diagnostic infrastructure, and rise in adoption of the innovative treatment approaches. Furthermore, collaborations between pharmaceutical companies, healthcare institutions, and research organizations are expected to accelerate the development of targeted therapies. Additionally, the advancements in genetic testing, and introduction of novel RNA-based therapies are expected to improve the disease management, and treatment outcomes for patients suffering from the acute intermittent porphyria.

Evaluation of Restraints in India Acute Intermittent Porphyria Market

Below are some major restraints and their influence on the market dynamics:

India Acute Intermittent Porphyria Market Challenges

Despite promising growth potential, India Acute Intermittent Porphyria Market is facing several challenges like high cost, limited access to specialized treatment, high dependence on import of orphan drugs, regulatory complexities, and inadequate reimbursement mechanisms. To overcome these challenges, stakeholders must focus on strengthening the rare disease awareness programs, expanding genetic testing capabilities, domestic pharmaceutical innovation, and improving patient access to affordable treatment through supportive healthcare policies.

India Acute Intermittent Porphyria Market Trends

Listed below are the major trends responsible for India Acute Intermittent Porphyria Market Growth:

• Rising Adoption of Genetic Testing: The increase in use of advanced DNA-based diagnostics is enabling more accurate identification of the acute intermittent porphyria cases across India.
• Shift Toward Targeted Therapies: The growth in preference for the RNA-based, and hemin therapies is improving the disease management, and reducing the frequency of acute attacks.
• Growth in Specialized Treatment Centers: The development of multi-specialty, and rare disease clinics is improving the access to expert care, and long-term patient monitoring.

Investment Opportunities in the India Acute Intermittent Porphyria Market

Given below are the investment opportunities available in India Acute Intermittent Porphyria Market:

• Development of Orphan Drugs: Strong investment opportunities are available for pharma companies to invest in the RNA-based, and novel therapies targeting the acute intermittent porphyria.
• Genetic Testing Labs: Investments made in affordable, and advanced diagnostic facilities can capture the growing demand for early, and accurate disease detection.
• Rare Disease Research Funding: Scope for funding is available in the clinical trials, and R&D collaborations to develop the innovative treatments, and improve disease understanding.
• Specialized Healthcare Infrastructure: Investments can be made in rare disease clinics, and hospital networks offering integrated diagnosis, and long-term patient management services.

Top Players in India Acute Intermittent Porphyria Market

Stated below are some of the leading companies holding majority of India Acute Intermittent Porphyria Market Share:

1. Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a leading global orphan drug, and rare disease-focused company, developing advanced therapies for rare metabolic disorders, and aligning with India’s growing emphasis on rare disease management, and specialty care.

2. Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals has a strong presence in specialty generics, and injectables, supporting hospital-based treatments, and potentially contributing to supportive care drugs used in managing AIP complications.

3. Recordati Rare Diseases (Recordati Group)

Recordati Group is a major global player in orphan drugs, directly relevant through its involvement in hemin-based therapies used for acute porphyria management, making it a core participant in AIP treatment.

4. Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical is one of India’s largest pharmaceutical companies with a strong chronic therapy portfolio, supporting hospital supply chains, and potential expansion into rare disease, and metabolic disorder treatments.

5. Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories focus on affordable specialty medicines, plays a key role in improving access to supportive therapies, and cost-effective rare disease treatment solutions in India.

Government Initiatives being implemented in the India Acute Intermittent Porphyria Market

According to Indian government data, the authorities are supporting the acute intermittent porphyria market through rare disease frameworks, and financial assistance under national health programs. Key efforts include the National Policy for Rare Diseases 2021, which provides funding support up to ₹50 lakh for eligible treatments, along with Ayushman Bharat PM-JAY, which offers the insurance coverage for economically weaker sections. The National Health Mission enhances the healthcare infrastructure, while the ICMR Rare Disease Registry supports the research, and better disease understanding across the country.

Future Insights of the India Acute Intermittent Porphyria Market

The India Acute Intermittent Porphyria market is expected to witness steady growth on account of advancements in genetic diagnostics, increase in adoption of RNA-based therapies, and expanding awareness of rare diseases. The future improvements in healthcare infrastructure will enhance early diagnosis, and treatment. The growth in pharmaceutical R&D investment, and international collaborations are likely to accelerate the innovation, while rise in patient registries will improve the disease tracking, and support the effective long-term management strategies.

Market Segmentation Analysis

The report offers a comprehensive study of the following market segments and their leading categories in India Acute Intermittent Porphyria Market:

By Diagnosis - Market Dominated by Blood Test, DNA Test Set for Rapid Expansion

According to Sachin, Senior Research Analyst, 6Wresearch, till 2025, blood test segment dominated the market, accounting for an estimated 39% market share, driven by its wide availability, low cost, and use as a primary screening tool in suspected cases. However, during 2026–2032, DNA test segment is expected to dominate the market, projected to grow at a CAGR of around 12.2%, supported by rising adoption of precision diagnostics, improved genetic testing infrastructure, and emphasis on definitive disease identification.

By Treatment - Prophylactic Hematin Infusions will Dominate the Market

Till 2025, prophylactic hematin infusions dominated the market, holding an estimated 56% market share, due to its established role as the standard acute attack management therapy in AIP patients. For the forecast period of 2026–2032, prophylactic hematin infusions will continue to dominate the market, growing at a CAGR of around 6.8%, driven by continued clinical reliance, strong physician preference, and large-scale availability of curative alternatives, despite gradual emergence of novel RNA-based therapies.

By End Users - Hospitals will lead the Market

Hospitals dominated the market till 2025, accounting for an estimated 64% market share, as most diagnosis, and infusion therapies are administered in tertiary care settings. During 2026–2032, hospitals are expected to remain dominant, projected to grow at a CAGR of around 9.1%, supported by expansion of specialty care units, improved rare disease management infrastructure, and increase in patient inflow for advanced diagnostic, and therapeutic services.

Note: Market size estimations and growth projections presented in this report are based on 6Wresearch’s advanced forecasting approach, validated with industry datasets as of June 2026.

Key Attractiveness of the Report:

• 10 Years of Market Numbers
• Historical Data Starting from 2022 to 2025
• Base Year: 2025
• Forecast Data until 2032
• Key Performance Indicators Impacting the Market
• Major Upcoming Developments and Projects

Key Highlights of the Report:

• India Acute Intermittent Porphyria Market Outlook
• Market Size of India Acute Intermittent Porphyria Market, 2025
• Forecast of India Acute Intermittent Porphyria Market, 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Revenues & Volume for the Period 2022- 2032
• India Acute Intermittent Porphyria Market Trend Evolution
• India Acute Intermittent Porphyria Market Drivers and Challenges
• India Acute Intermittent Porphyria Price Trends
• India Acute Intermittent Porphyria Porter's Five Forces
• India Acute Intermittent Porphyria Industry Life Cycle
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Diagnosis for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Blood Test for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Urine Test for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By DNA Test for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Serum Test for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Treatment for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Gonadotropin-Releasing Hormone Analogues for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Prophylactic Hematin Infusions for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By End Users for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Hospitals for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Clinics for the Period 2022- 2032
• Historical Data and Forecast of India Acute Intermittent Porphyria Market Revenues & Volume By Research Centers for the Period 2022- 2032
• India Acute Intermittent Porphyria Import Export Trade Statistics
• Market Opportunity Assessment By Diagnosis
• Market Opportunity Assessment By Treatment
• Market Opportunity Assessment By End Users
• India Acute Intermittent Porphyria Top Companies Market Share
• India Acute Intermittent Porphyria Competitive Benchmarking By Technical and Operational Parameters
• India Acute Intermittent Porphyria Company Profiles
• India Acute Intermittent Porphyria Key Strategic Recommendations

Market Covered

The report offers an extensive study of the following market segments:

By Diagnosis

• Blood Test
• Urine Test
• DNA Test
• Serum Test

By Treatment

• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

By End Users

• Hospitals
• Clinics
• Research Centers